Spero Therapeutics, Inc. (SPRO): COO Timothy Keutzer to retire

Events in this filing

Item 5.02 as filed

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b)  On October 26, 2026, Spero Therapeutics, Inc. (the “Company”) announced that Timothy Keutzer, the Company’s Chief Operating Officer, will retire from the Company effective as of December 31, 2026 (the “Effective Date”). In connection with his retirement, the Company expects to enter into a consulting arrangement with Mr. Keutzer on or about the Effective Date, pursuant to which Mr. Keutzer will provide advisory services to the Company in support of the transition until approximately February 28, 2027, unless earlier terminated by either party on fifteen days’ prior written notice (the “Consulting Period”). Pursuant to the terms of the Consulting Agreement, Mr. Keutzer will be paid an hourly rate for his services during the Consulting Period. Mr. Keutzer’s retirement follows 11 years of dedicated service, leadership and significant contributions to the Company.